RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of ...

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB. – It feels very exciting. CSL is an interesting company, ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

This is based on its forecast for strong double-digit earnings growth for the foreseeable future thanks to the CSL Behring plasma business. UBS is also bullish on CSL and has a buy rating and $330 ...

Whilst some of these developments have led to structural changes to CSL's business, we believe the company's proactive investments in its IG franchise and new product launches in the Behring ...

After hours: February 3 at 5:59:47 PM EST Loading Chart for CSL ...

For the first time in almost 20 years, Walmart has a new logo. The international retailer describes it as a “a comprehensive brand refresh,” but the online world hasn’t been quite so kind to ...